Loading
Somatostatin receptor-positive means a neuroendocrine tumour takes up a DOTATATE tracer on PET. It is the requirement for lutetium-177 dotatate and the marker that predicts response to octreotide and lanreotide.
Gallium-68 or copper-64 DOTATATE PET (Netspot, Detectnet) images SSTR2; the Lutathera label covers somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, including foregut, midgut and hindgut, in adults and children 12 and over, with the NETTER-1 trial requiring uptake at least equal to liver (Krenning score 2 or higher) on every lesion. The Krenning scale (0 to 4, from no uptake to greater than spleen or kidney) is the historic scintigraphy score carried over to PET. Actinium-225 DOTATATE and other radioligands in trials use the same selection.
In plain words · Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.
A DOTATATE PET scan that lights up your tumour at least as brightly as your liver makes it somatostatin receptor-positive, which is needed for lutetium-177 dotatate and predicts benefit from the monthly somatostatin injections. Tumours that do not take up the tracer, often the fast-growing ones, need a different plan.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
Tumour uptake of a somatostatin receptor PET tracer at least equal to normal liver (Krenning score 2 or higher) in target lesions; the Lutathera label states 'somatostatin receptor-positive' without a numeric cut-off.
“LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.”
Lutathera prescribing information| Threshold | Drug | Cancer | Regulator | Source |
|---|---|---|---|---|
| Somatostatin receptor-positive by SSTR imaging | Lutetium-177 dotatate | Neuroendocrine tumours | FDA | label |
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares Actinium-225 DOTATATE, Lutetium-177 dotatate, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Ki-67 index (proliferation by IHC) and the tag biomarker.
Shares Theranostics, Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours.
Shares Ki-67 index (proliferation by IHC) and the tag biomarker.
Shares Ki-67 index (proliferation by IHC), Neuroendocrine tumour grade (Ki-67) and WHO classification, Neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Lutetium-177 dotatate, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares PSMA expression by PET (PSMA-positive) and the tag biomarker.
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/